Dementia is advancing at an unprecedented rate—every three seconds, another person is diagnosed. Currently, 55 million people worldwide live with dementia, and by 2050, that number could soar to 139 million. These figures aren’t mere statistics; they represent individuals, families, and communities facing complex, life-altering challenges. For primary care providers, who often stand as the first line of defense, this signals a crucial need for precise, sensitive tools to enable early detection. Anything less would be inadequate for addressing the scope and complexity of this global health crisis.
Outdated detection tools: Failing modern health care needs
In my 30-plus years as a neuroscientist dedicated to understanding the brain, I’ve witnessed remarkable progress in our knowledge of its intricate networks and functions. But while dementia research has evolved dramatically, the tools available to primary care physicians remain rooted in outdated methods, unable to match our current understanding of brain health. Standard cognitive assessments often lack the necessary nuance to identify the subtle changes that occur in the early stages of cognitive decline. More critically, these tools are rarely able to distinguish between conditions such as Alzheimer’s, depression, or traumatic brain injury, which each require different interventions. The result? Diagnostic accuracy suffers, delaying essential care, prolonging suffering for patients and families, and overburdening health care systems already operating at capacity.
Today, 75 percent of dementia cases worldwide are missed or misdiagnosed, particularly during the crucial early stages when intervention could significantly alter the course of the disease. This is occurring in an era when our ability to sequence genomes, analyze neural pathways, and monitor biomarkers has expanded vastly. And yet, the primary tools used by health care providers—such as the Mini-Mental State Examination (MMSE), Saint Louis University Mental Status (SLUMS), and the Montreal Cognitive Assessment (MoCA)—were developed decades ago. These tests, while once groundbreaking, struggle to capture early, subtle signs of cognitive impairment and often fall short in diverse and non-standard cases, including early-onset dementia or patients from varied cultural and educational backgrounds. Research confirms they offer limited utility in distinguishing normal age-related decline from mild cognitive impairment (MCI), a critical precursor to dementia.
While these tools offer a surface approach to cognitive assessment, the alternative of neuropsychological testing also has its limitations. Frequently considered the “gold standard” for their in-depth and domain-specific insights, neuropsychological tests are time-intensive, often requiring two to three hours to complete, special training to administer, and extensive analysis, making them impractical for the fast-paced demands of modern health care. As such, these “gold standard” assessments remain largely inaccessible to patients and providers who need timely, actionable information.
The price of missed and misdiagnosed dementia
The repercussions of missed or delayed dementia diagnoses are profound. Early detection enables patients and families to take proactive steps—managing the disease, planning for the future, and accessing support services. When a diagnosis is delayed, patients and their loved ones are forced to make difficult decisions under more distressing circumstances, often facing fewer options for effective care.
On a broader scale, the cost to health care systems is staggering. In the U.S. alone, dementia-related care costs exceed $300 billion annually—a figure projected to climb sharply without targeted, preventive measures. Delayed or missed diagnoses drive up emergency room visits, hospitalizations, and long-term care needs, compounding both human and economic costs. Frequent hospitalizations for dementia-related complications lead to sky-high expenses that could otherwise be minimized. Moreover, without effective dementia management, patients may end up in costly long-term care facilities sooner than necessary—an outcome that goes against the wishes of 77 percent of patients who prefer home treatment, according to the Delaware Journal of Public Health.
It’s clear that a failure to act early is a fast track to escalating health care costs, burdening both systems and patients alike.
Matching detection tools to our advances in brain science
Decades of neuroscience research have greatly advanced our understanding of how dementia uniquely affects different brain regions and cognitive functions. Imagine a tool that can precisely measure these functions, allowing clinicians to accurately distinguish between cognitive disorders and create personalized care plans. These tools are not just theoretical; they already exist. However, adoption among primary care providers remains limited, hindered by practical challenges, gaps in awareness, and barriers to integration in frontline health care.
Addressing these challenges is essential to tackling the dementia crisis. Investing in high-quality, digitally-enabled cognitive assessment tools—rigorously validated through clinical research and built on the latest brain science—will be critical. These tools should detect early cognitive changes, accurately differentiate types of impairment, and provide actionable insights. Equally important, they must be accessible to all health care providers, from urban hospitals to rural clinics, so early intervention can become the rule, not the exception.
With the right resources we have the potential to transform dementia care—shifting from a reactive to a proactive model and building a future of early intervention that upholds the dignity, autonomy, and potential of each individual facing this diagnosis.
Adrian Owen is a neuroscientist.
